EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Avoiding Treatment in Hospital With Subcutaneous Furosemide for Worsening Heart Failure

Marvin A Konstam, Joseph Massaro, Ravi Dhingra, Mary Walsh, Linda Ordway, Michael S Pursley, Dalton S McLean, Sandeep Saha, Nicole Close, Jeremy M Konstam, Katherine H Luepke, John F Mohr und 1 weitere

JACC: Heart Failure · 2024-11 · 12 (11) · 1830-1841

DOI: 10.1016/j.jchf.2024.07.015 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift JACC: Heart Failure, 2024-11. Verfasst von Marvin A Konstam und 12 weiteren Autor:innen. Beteiligte Einrichtung: Tufts Medical Center, and Tufts University School of Medicine, Boston, Massachusetts, USA. Electronic address: Marvin.Konstam@tuftsmedicine.org. Hauptthemen laut MEDLINE: Furosemide, Heart Failure, Diuretics. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Therapies are needed to address worsening congestion, without hospitalization, in patients with chronic heart failure (HF). OBJECTIVES: This pilot study assessed outcomes of a novel subcutaneous (SC) furosemide formulation compared to usual care in outpatients with worsening congestion. METHODS: Participants with chronic HF and worsening congestion were randomized open-label 2:1 to SC furosemide compared to usual care (UC). Decongestion was estimated by tracking body weight. The primary endpoint was a win ratio of a 30-day hierarchical composite of cardiovascular death, HF events, and change in N-terminal pro-B-type natriuretic peptide. Secondary endpoints included dyspnea severity, functional capacity, and quality of life. RESULTS: Thirty-four participants were randomized to SC furosemide and 17 to UC. SC furosemide caused greater reduction in body weight: between-group difference in least square mean change was -2.02 kg at day 3 (95% CI: -3.9 to -0.14; P = 0.035). SC furosemide-to-UC win ratio was 1.11 (95% CI: 0.48-2.50; P = 0.806). Significant between-group least square mean differences favoring SC furosemide occurred in 7-point dyspnea score (P = 0.017) and 6-minute walk test (P = 0.032), with trend in Kansas City Cardiomyopathy Questionnaire (KCCQ)-12 Overall Summary Score of 9.15 (95% CI: 1.95-20.3; P = 0.106). The most common related adverse event with SC furosemide was mild infusion site pain (11.8%). CONCLUSIONS: SC furosemide augmented weight loss in patients with HF and worsening congestion. The composite primary endpoint was not statistically significant in this pilot investigation. However, findings of improved dyspnea scores and functional capacity, with favorable trend in KCCQ-12 score, warrant additional investigation to further document the clinical value of SC furosemide as an alternative to hospitalization (AT HOME-HF [Avoiding Treatment in the Hospital With Furoscix for the Management of Congestion in Heart Failure-A Pilot Study]; NCT04593823).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

FurosemideHeart FailureDiureticsHumansPilot ProjectsMaleFemaleAgedInjections, SubcutaneousQuality of LifeMiddle AgedNatriuretic Peptide, BrainDisease ProgressionDyspneaHospitalizationPeptide FragmentsTreatment OutcomeAged, 80 and over

Stichwörter der Autor:innen

congestiondiuretic agentsfurosemideheart failureoutpatientsubcutaneous

Substanzen

FurosemideDiureticsNatriuretic Peptide, Brainpro-brain natriuretic peptide (1-76)Peptide Fragments

Autor:innen und Institutionen

  • Tufts Medical Center, and Tufts University School of Medicine, Boston, Massachusetts, USA. Electronic address: Marvin.Konstam@tuftsmedicine.org.
  • Boston University School of Public Health, Boston, Massachusetts, USA.
  • University of Wisconsin, Madison, Wisconsin, USA.
  • Ascension St Vincent Heart Center, Indianapolis, Indiana, USA.
  • Tufts Medical Center, and Tufts University School of Medicine, Boston, Massachusetts, USA.
  • Eastern Shore Research Institute, Fairhope, Alabama, USA.

Zitieren

APA

Konstam, M. A., Massaro, J., Dhingra, R., Walsh, M., Ordway, L., Pursley, M. S., McLean, D. S., Saha, S., Close, N., Konstam, J. M., Luepke, K. H., Mohr, J. F., & Udelson, J. E. (2024). Avoiding Treatment in Hospital With Subcutaneous Furosemide for Worsening Heart Failure. JACC: Heart Failure, 12(11), 1830-1841. https://doi.org/10.1016/j.jchf.2024.07.015

Vancouver

Konstam MA, Massaro J, Dhingra R, Walsh M, Ordway L, Pursley MS, et al. Avoiding Treatment in Hospital With Subcutaneous Furosemide for Worsening Heart Failure. JACC: Heart Failure. 2024;12(11):1830-1841. doi:10.1016/j.jchf.2024.07.015

BibTeX
@article{Konstam2024,
  author = {Konstam, Marvin A and Massaro, Joseph and Dhingra, Ravi and Walsh, Mary and Ordway, Linda and Pursley, Michael S and McLean, Dalton S and Saha, Sandeep and Close, Nicole and Konstam, Jeremy M and Luepke, Katherine H and Mohr, John F and Udelson, James E},
  title = {Avoiding Treatment in Hospital With Subcutaneous Furosemide for Worsening Heart Failure},
  journal = {JACC: Heart Failure},
  year = {2024},
  volume = {12},
  number = {11},
  pages = {1830--1841},
  doi = {10.1016/j.jchf.2024.07.015}
}
Kostenlos starten →